Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
189 hedge funds and large institutions have $1.61B invested in Cymabay Therapeutics in 2023 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 57 increasing their positions, 52 reducing their positions, and 24 closing their positions.
163% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 24
59% more capital invested
Capital invested by funds: $1.02B → $1.61B (+$598M)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
25% more funds holding
Funds holding: 151 → 189 (+38)
10% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 52
7% more call options, than puts
Call options by funds: $35M | Put options by funds: $32.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$92M |
| 2 |
Holocene Advisors
New York
|
+$41.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.2M |
| 4 |
FAM
Fred Alger Management
New York
|
+$28.8M |
| 5 |
Jennison Associates
New York
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$22.2M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$21M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$19.8M |
| 4 |
Millennium Management
New York
|
-$17.2M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$12.5M |
CBAY Hedge Fund Activity: Q3 2023 in Review
189 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2023, worth a combined $1.61B — up 59% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new CBAY positions and 24 closed out — a net gain of 39 holders — while 57 added to existing stakes and 52 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $92M. The largest seller was Commodore Capital, exiting entirely with an estimated $22.2M sold.
- 189 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2023, up from 151 in Q2 2023.
- Funds reported $1.61B of Cymabay Therapeutics stock for Q3 2023, up 59% quarter-over-quarter.
- 63 funds opened new Cymabay Therapeutics positions in Q3 2023 and 24 closed out, a net change of +39 holders.
- The largest Cymabay Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $92M added.
- The largest Cymabay Therapeutics seller in Q3 2023 was Commodore Capital, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2023.